Relay Therapeutics Surges on Promising Vascular Anomaly Data
Relay Therapeutics shares surged 11.3% premarket after reporting a 60% volumetric response rate from its Phase 2 trial of zovegalisib for vascular anomalies, with no patient discontinuations due to adverse events.
Technology
